Avalere Health...

Vaccination Quality Measures

Current landscape & what's coming next

Presented to the National Adult Influenza and Immunization Summit

EVERY TIENT POSSIBLE



Agenda.

- Vaccination quality measures
- How and where they're used
- Financial implications

Future implications

- ACIP overhaul
- Shifting COVID-19 vaccine indications
- Vaccine perceptions and attitudes
- Stakeholder impact

Composite vaccination measures aim to reflect immunization delivery across the life course.

While standalone measures are still used in some programs, composite measures are more common.

CIS

Childhood Immunization Status

 Percentage of children aged ≥2 years who had 4 DTaP, 3 IPV, 1 MMR, 3 Hib, 3 HepB, 1 VZV, 4 PCV, 1 HepA, 2 or 3 RV, and 2 influenza vaccines by their second birthday

IMA

Immunizations for Adolescents

 Percentage of adolescents aged ≥13 years who had 1 dose meningococcal vaccine, 1 Tdap vaccine, and a full HPV series by their thirteenth birthday

AIS

Adult Immunization Status

 Percentage of members aged ≥19 years who are up to date on recommended routine vaccines for influenza, Td/Tdap, zoster, hepatitis B, and pneumococcal

PRS

Prenatal Immunization Status

 Percentage of deliveries during the measurement period in which women received influenza and Tdap vaccinations

Overview

Composite measures are stewarded by NCQA but used broadly.

	Measure	Program/Measure Set					
		NCQA HEDIS®	Medicare QPP MIPS	MSSP	Medicaid Child Core Set	Medicaid Adult Core Set	MA Star Ratings
	CIS	X			X		
	IMA	X			X		
	AIS	X	X	X		X	X *
	PRS	X			X	X	

Different programs leverage different payment incentives and disincentives with the goal of improving vaccine uptake.


Different quality programs leverage varying financial incentives.



Ratings are published publicly and have impact to reputation. Measures commonly used in commercial, Medicare, Medicaid, and exchange value-based arrangements.



Incentives and disincentives vary by state; CMS will withhold federal Medicaid payments from states that do not comply with mandatory Core Set reporting.



Participants earn a payment adjustment (positive or negative) for Part B covered services based on performance across categories.



Incentives and disincentives vary by state. Adult immunization measures are voluntary for reporting.



ACO participants may be eligible for shared savings or shared risk at varied levels depending on track.



Performance on measures affects plan ratings, which are used to determine bonus payments.

Measures tied to payment are more likely to drive behavior change. One study found that paying providers \$200 more per patient for meeting performance criteria resulted in care improvements.

The evolving federal landscape could have varying implications for vaccination quality measures.

ACIP overhaul

Shifting COVID-19 vaccine indications

Vaccine perceptions and attitudes

RFK Jr.'s replacement of ACIP membership calls vaccine recommendations into question.

How guidelines inform measure development:

Measure specifications rely on clinical practice guidelines.

Ex.

When developing new measures for HEDIS, NCQA aligns specifications with ACIP recommendations.

New or revised recommendations result in new or revised quality measures.

Ex.

COVID-19 vaccine recommendations for adults led to NCQA's in-progress revision of AIS to include COVID-19 vaccination


The Committee's intent to revisit existing recommendations could result in 2 scenarios for HEDIS composite measures:


NCQA revises HEDIS measures to align with updated recommendations, reducing the number of vaccines included and/or narrowing applicable populations.

NCQA pivots to alternative sources for vaccination guidance to inform measure development (e.g., AAP, AAFP, Vaccine Integrity Project).

Future Implications – Shifting COVID-19 Vaccine Indications

Narrower COVID-19 vaccine indications have already affected quality measure updates.





The ACIP expressed consideration of a narrower, risk-based recommendation for COVID-19 vaccines (vs. the current universal recommendation for everyone aged ≥6 months.



NCQA announced its proposed COVID-19 indicator for AIS would apply to adults aged ≥65 years.



HHS announced the removal of COVID-19 vaccination recommendations for healthy children and pregnant people. The recommendation for children was subsequently changed from routine to SCDM.

Future Implications – Vaccine Perceptions and Attitudes

CMS proposals to remove COVID-19 measures from post-acute quality programs could indicate deprioritization.

CMS proposed removing the "COVID-19 Vaccine: Percent of Patients/Residents Who Are Up to Date" measure from two quality reporting programs:

Inpatient Rehabilitation Facility QRP

Home Health QRP

Measure removal was proposed based on:

Removal Factor 8: "The costs associated with a measure outweigh the benefit of its continued use in the program."



Providers noted concerns about data collection challenges and increased administrative burden.



CMS noted declining COVID-19 cases and deaths among older adults.

CMS's stated perception of reduced COVID-19 disease burden among older adults may not align with the latest recommendations and indications for COVID-19 vaccines, which prioritize older adults.

Future Implications – Stakeholder Impact

The changing vaccine policy environment could influence changes to quality measures with downstream impacts on providers and patients.




203 million people

are covered by health plans that report HEDIS



60,000 clinicians

Work in an NCQA-recognized medical practice



Shifting measure specifications to align with changing guidelines could result in confusion among providers.

Thank you.

